Loading
companiesCompany
Lantern Pharma
Lantern Pharma is a Texas company that uses its RADR machine-learning platform to revive shelved cancer drugs; LP-184 is a DNA-damaging agent activated in tumours with DNA repair defects, including glioblastoma.
Also called: Lantern Pharma Inc.NASDAQ:LTRN
Overview
Lantern Pharma applies its RADR artificial-intelligence platform to match small molecules with the tumours and biomarkers most likely to respond. LP-184 is an acylfulvene prodrug activated by the enzyme PTGR1 that causes DNA damage in cells with defective nucleotide excision repair; it is in phase 1 trials in solid tumours and, as LP-184 for glioblastoma, holds orphan and fast track designations. LP-284 targets B-cell lymphomas and LP-300 is in a phase 2 trial in never-smokers with lung adenocarcinoma.
Headquarters
Dallas, Texas, US
Scorecard
All companies#464of 1244 companies, score 6
- phase 1/2 +1
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 0 targets, 2 registry studies. Formula on the scorecards page.
Type
Biotech · NASDAQ:LTRN
Stage
Public
Website
Founded
2013
Phase 2Small-molecule inhibitor
LP-184 is a small-molecule inhibitor from Lantern Pharma Inc., in registered phase 2 trials for triple-negative breast cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma.
drugs
Phase 2Small-molecule inhibitor